FDA Approves New Treatment Option: EGFR exon 19 deletions or exon 21 L858R mutations

[NikoleV]

The US Food and Drug Administration (FDA) approved a new treatment option for people newly diagnosed with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations. 

The recent approval offers a new chemotherapy-free treatment for patients—the combination of lazertinib (Lazcluze™) with amivantamab-vmjw (Rybrevant®).  

Learn more by visiting https://brnw.ch/21wM1KK